Archive

Neovasc Reducer™ for Treatment of Refractory Angina Featured in Sponsored Session at the 40th Annual National Congress of the Italian Society of Interventional Cardiology

®NASDAQ, TSX: NVCN VANCOUVER, Oct. 22, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today...

Read More

Neovasc Retains Westwicke, ICR for Integrated Communications Counsel

®NASDAQ, TSX: NVCN VANCOUVER, Oct. 16, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced...

Read More

Neovasc Announces Notice of US Patent Granted for Tiara™ Transcatheter Device for Treatment of Severe Mitral Regurgitation

®NASDAQ, TSX: NVCN VANCOUVER, Oct. 15, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced...

Read More

Neovasc and GADA® Sponsor Session at the 40th Annual (GISE) National Congress of the Italian Society of Interventional Cardiology

®NASDAQ, TSX: NVCN VANCOUVER and MILAN, Oct. 09, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...

Read More

Neovasc’s Tiara™ for Treatment of Mitral Regurgitation and Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference

NASDAQ, TSX: NVCN VANCOUVER, Sept. 30, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More